News | October 25, 2010

Dutch Court Rules in Favor of Occlutech in AGA Patent Case

October 25, 2010 – The Hague, Netherlands ruled in favor of Occlutech, a transcatheter structural heart occluder device maker, in the ongoing patent litigation with AGA Medical. The lawsuit stems from AGA alleging Occlutech’s technology infringes on its Amplatzer transcatheter occluder device patents.

AGA had appealed the court ruling in Occlutech’s favor in 2008. In the new ruling, the appeal court of The Hague saw no reason to change the favorable first instance ruling. The Dutch appeal court decision is similar to the appeals court rulings in the United Kingdom, which were received in mid-2010. The rulings are subject to further appeal by AGA.

Occlutech lost in the German district and appeal courts of Dusseldorf in 2007 and 2008, causing a halt of sales and manufacturing activities in Germany. But the German Supreme Court, (BGH), recently announced that it has allowed Occlutech's appeal. Occlutech expects a final decision in the first half of 2011.

If that case is decided in Occlutech's favor, the company said it plans to seek substantial claims for repayments and damages. Due to the litigation activity, Occlutech has lost revenue, had products destroyed and suffered the cost of litigation leading to potential damage claims in excess EUR 50 million.

AGA was recently purchased by St. Jude Medical.

For more information: www.occlutech.com


Related Content

News | Structural Heart Occluders

June 20, 2024 — atHeart Medical, a medical device company establishing a new standard of care for atrial septal defects ...

Home June 20, 2024
Home
News | Structural Heart Occluders

July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the ...

Home July 14, 2023
Home
News | Structural Heart Occluders

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...

Home May 05, 2022
Home
News | Structural Heart Occluders

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

Home October 04, 2021
Home
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
News | Structural Heart Occluders

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

Home April 20, 2021
Home
Videos | Structural Heart Occluders

Interview with Carey Kimmelstiel, M.D., FACP, FACC, director, cardiac catheterization laboratory, director ...

Home March 24, 2020
Home
Technology | Structural Heart Occluders

June 10, 2019 – W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket ...

Home June 10, 2019
Home
News | Structural Heart Occluders

March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective ...

Home March 27, 2019
Home
News | Structural Heart Occluders

February 13, 2019 — Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo ...

Home February 13, 2019
Home
Subscribe Now